Seasonal Influenza Vaccines – US Drug Forecast and Market Analysis to 2025

Categories: Drugs by Therapeutic Area, Infectious Diseases Drugs, Pharmaceuticals

Price: $4,995


Seasonal Influenza Vaccines - US Drug Forecast and Market Analysis to 2025


Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses, designated as influenza Type A, B, and C. The infection’s rapid onset and potential for high morbidity and mortality, particularly in high-risk patient populations such as the elderly and young children, make prompt and effective treatment with antiviral medication very difficult. For these reasons, prophylactic vaccination is the preferred intervention for seasonal influenza.

The US will experience solid growth in seasonal influenza vaccine sales during the forecast period, and this growth will be driven by a significant shift in the market share distribution of the different vaccine types. The US market will experience the largest nominal change of any country in the 7MM.


- Overview of Seasonal Influenza Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2015-2025.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Seasonal Influenza Vaccines market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Seasonal Influenza Vaccines.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2015-2025 in the US.

Table of Contents

1. List of Tables and Figures

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Related Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.1.3 Symptoms and Prognosis

4 Disease Management

4.1 Seasonal Influenza Immunization Policy

4.1.1 Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines

4.2 US

4.2.1 Influenza Immunization Recommendations and Policies

4.2.2 Clinical Practice

5 Competitive Assessment

5.1 Overview

5.2 Product Profiles - Major Brands, Inactivated Vaccines

5.2.1 Fluzone Quadrivalent

5.2.2 Fluzone High-Dose

5.2.3 Fluzone Intradermal

5.2.4 Vaxigrip

5.2.5 Fluarix Tetra

5.2.6 Fluvirin

5.2.7 Afluria

5.2.8 Agrippal

5.3 Product Profiles - Major Brands, Inactivated Vaccines (Adjuvanted)

5.3.1 Fluad

5.4 Product Profiles - Major Brands, Live-Attenuated Vaccines

5.4.1 FluMist Quadrivalent

5.5 Product Profiles - Major Brands, Cell Cultured Vaccines

5.5.1 Flublok

5.5.2 Flucelvax

5.6 Other Seasonal Influenza Vaccines

5.6.1 Influvac

5.6.2 Minor Brands

6 Unmet Needs and Opportunity Analysis

6.1 Overview

6.2 Higher Level of Public Awareness and Positive Perception of Influenza Vaccines

6.2.1 Unmet Need

6.2.2 Gap Analysis

6.2.3 Opportunity

6.3 Immunization Policies Targeting Children and Adolescents

6.3.1 Unmet Need

6.3.2 Gap Analysis

6.3.3 Opportunity

6.4 Enhanced Vaccine Efficacy in High-Risk Groups

6.4.1 Unmet Need

6.4.2 Gap Analysis

6.4.3 Opportunity

6.5 Vaccines Leveraging Innovative and Efficient Manufacturing Technologies

6.5.1 Unmet Need

6.5.2 Gap Analysis

6.5.3 Opportunity

6.6 Improving the Cost-Effectiveness of Influenza Vaccines

6.6.1 Unmet Need

6.6.2 Gap Analysis

6.6.3 Opportunity

6.7 Vaccines with Broader Influenza Strain Coverage

6.7.1 Unmet Need

6.7.2 Gap Analysis

6.7.3 Opportunity

6.8 Improved Vaccine Safety Profile

6.8.1 Unmet Need

6.8.2 Gap Analysis

6.8.3 Opportunity

7 Pipeline Assessment

7.1 Overview

7.2 Promising Vaccines in Clinical Development

7.2.1 Seasonal Influenza VLP Vaccine

7.2.2 VN-100

7.2.3 Quadrivalent Seasonal Influenza VLP Vaccine

7.3 Promising Vaccines in Early-Stage Development

7.3.1 FLU-v

7.3.2 M-001

7.3.3 TAK-850

7.3.4 VAX-2012Q

7.4 Other Vaccines in Development Outside the 7MM

8 Market Outlook

8.1 US

8.1.1 Forecast

8.1.2 Key Events

8.1.3 Drivers and Barriers

9 Appendix

9.1 Bibliography

9.2 Abbreviations

9.3 Methodology

9.4 Forecasting Methodology

9.4.1 Vaccine Coverage

9.4.2 Vaccines Included

9.4.3 Key Launch Dates

9.4.4 Influenza Vaccine Tender System Assumptions

9.4.5 General Pricing Assumptions

9.4.6 Individual Vaccine Assumptions

9.4.7 Pricing of Pipeline Agents

9.5 Primary Research - KOLs Interviewed for this Report

9.6 Primary Research - Prescriber Survey

9.7 About the Authors

9.7.1 Analyst

9.7.2 Therapy Area Director

9.7.3 Epidemiologists

9.7.4 Director of Epidemiology

9.7.5 Global Director of Therapy Analysis and Epidemiology

9.8 About

9.9 Disclaimer

List of Tables

Table 1: Notable Influenza Pandemics

Table 2: Influenza Symptoms

Table 3: Seasonal Influenza Immunization Recommendation Agencies by Country, 2016

Table 4: Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines, 2016

Table 5: Country Profile - US

Table 6: Leading Seasonal Influenza Vaccines, 2016

Table 7: Product Profile - Fluzone Quadrivalent

Table 8: Immunogenicity Profile of Fluzone Quadrivalent

Table 9: Local and Systemic AEs of Fluzone Quadrivalent

Table 10: Fluzone Quadrivalent SWOT Analysis, 2016

Table 11: Global Sales Forecast ($m) for Fluzone Quadrivalent, 2015-2025

Table 12: Product Profile - Fluzone High-Dose

Table 13: Immunogenicity of Fluzone High-Dose Compared with Fluzone

Table 14: Local and Systemic AEs of Fluzone High-Dose

Table 15: Fluzone High-Dose SWOT Analysis, 2016

Table 16: Global Sales Forecast ($m) for Fluzone High-Dose, 2015-2025

Table 17: Product Profile - Fluzone Intradermal

Table 18: Comparison of Fluzone Intradermal Quadrivalent Versus Fluzone Intradermal Trivalent

Table 19: Local andsystemic AEs of Fluzone Intradermal Quadrivalent

Table 20: Fluzone Intradermal Quadrivalent SWOT Analysis, 2016

Table 21: Global Sales Forecast ($m) for Fluzone/Intanza Intradermal, 2015-2025

Table 22: Product Profile - Vaxigrip

Table 23: Cumulative Incidence of Influenza Infection in Children

Table 24: Local and Systemic AEs of Vaxigrip

Table 25: Vaxigrip SWOT Analysis, 2016

Table 26: Global Sales Forecast ($m) for Vaxigrip, 2015-2025

Table 27: Product Profile - Fluarix Tetra

Table 28: Immunogenicity Profile of Fluarix Tetra

Table 29: Local and Systemic AEs of Fluarix Tetra

Table 30: Fluarix Tetra SWOT Analysis, 2016

Table 31: Global Sales Forecast ($m) for Fluarix Tetra, 2015-2025

Table 32: Product Profile - Fluvirin

Table 33: Immunogenicity of Fluvirin in Adults

Table 34: Local and Systemic AEs of Fluvirin

Table 35: Fluvirin SWOT Analysis, 2016

Table 36: Global Sales Forecast ($m) for Fluvirin, 2015-2025

Table 37: Product Profile - Afluria

Table 38: Immunogenicity of Afluria in Adults

Table 39: Local and Systemic AEs of Afluria

Table 40: Afluria SWOT Analysis, 2016

Table 41: Global Sales Forecast ($m) for Afluria, 2015-2025

Table 42: Product Profile - Agrippal

Table 43: Immunogenicity of Agrippal

Table 44: Local and Systemic AEs of Agrippal

Table 45: Agrippal SWOT Analysis, 2016

Table 46: Global Sales Forecast ($m) for Agrippal, 2015-2025

Table 47: Product Profile - Fluad

Table 48: Immunogenicity Comparison of Fluad Versus Agriflu

Table 49: Local and Systemic AEs of Fluad

Table 50: Fluad SWOT Analysis, 2016

Table 51: Global Sales Forecast ($m) for Fluad, 2015-2025

Table 52: Product Profile - FluMist Quadrivalent

Table 53: Noninferiority of FluMist Quadrivalent Compared with FluMist Trivalent

Table 54: AEs of FluMist Quadrivalent

Table 55: FluMist Quadrivalent SWOT Analysis, 2016

Table 56: Global Sales Forecast ($m) for FluMist Quadrivalent, 2015-2025

Table 57: Product Profile - Flublok

Table 58: Immunogenicity of Flublok compared with Fluzone and Fluzone High-Dose

Table 59: Local and Systemic AEs of Flublok

Table 60: Flublok SWOT Analysis, 2016

Table 61: Global Sales Forecast ($m) for Flublok, 2015-2025

Table 62: Product Profile - Flucelvax

Table 63: Immunogenicity of Flucelvax

Table 64: Local and Systemic AEs of Flucelvax

Table 65:Flucelvax SWOT Analysis, 2016

Table 66: Global Sales Forecast ($m) for Flucelvax, 2015-2025

Table 67: Summary of Other Marketed Seasonal Influenza Vaccines, 2016

Table 68: Unmet Need and Opportunity in Seasonal Influenza Vaccines, 2016

Table 69: Seasonal Influenza Vaccines - Late-Stage Pipeline, 2016

Table 70: Quadrivalent Versions of Marketed Vaccines

Table 71: Product Profile - Seasonal Influenza VLP Vaccine

Table 72: Seasonal Influenza VLP Vaccine SWOT Analysis, 2016

Table 73: Global Sales Forecast ($m) for Seasonal Influenza VLP Vaccine, 2015-2025

Table 74: Product Profile - VN-100

Table 75: Comparison of Immunogenicity Profile of VN-100 and Subcutaneous Standard Vaccine

Table 76: Frequency of Local and Systemic AEs of VN-100 Compared with a Comparator Subcutaneous Vaccine

Table 77: VN-100 SWOT Analysis, 2016

Table 78: Global Sales Forecast ($m) for VN-100, 2015-2025

Table 79: Product Profile - Quadrivalent Seasonal Influenza VLP Vaccine

Table 80: Quadrivalent Seasonal Influenza VLP Vaccine SWOT Analysis, 2016

Table 81: Global Sales Forecast ($m) for Quadrivalent Seasonal Influenza VLP Vaccine, 2015-2025

Table 82: Promising Vaccines in Early-Stage Development, 2016

Table 83: Summary of Seasonal Influenza Vaccines in Development Outside the 7MM, 2016

Table 84: Sales Forecasts ($m) for Seasonal Influenza Vaccines in the US, 2015-2025

Table 85: Key Events Impacting Sales for Seasonal Influenza in the US, 2015?2025

Table 86: US Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015?2025

Table 87: Key Launch Dates

Table 88: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

Figure 1: Influenza Virus Structure

Figure 2: Seasonal Influenza Vaccines - Phase II/Phase III Pipeline, 2016

Figure 3: Competitive Assessment of the Late-Stage Pipeline Vaccines for Seasonal Influenza, 2015-2025

Figure 4: Sales of Seasonal Influenza Vaccines by Class in the US, 2015 and 2025